ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.32M | -51.15M | -44.88M | -33.94M | 49.93M |
| Total Depreciation and Amortization | 417.00K | 391.00K | 279.00K | 280.00K | 29.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.89M | 4.78M | 6.06M | 3.34M | 2.72M |
| Change in Net Operating Assets | -7.46M | -1.07M | -1.05M | -10.42M | -10.68M |
| Cash from Operations | -43.49M | -47.05M | -39.59M | -40.74M | 42.00M |
| Capital Expenditure | 0.00 | -197.00K | -51.00K | -91.00K | -302.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.11M | -44.78M | 48.62M | 29.16M | -101.46M |
| Cash from Investing | 24.11M | -44.98M | 48.57M | 29.06M | -101.76M |
| Total Debt Issued | -1.49M | 97.75M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.78M | 479.00K | 2.70M | 725.00K | 1.53M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 844.00K | 1.82M | -- | -- | 69.38M |
| Cash from Financing | 1.13M | 100.05M | 2.70M | 725.00K | 70.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.24M | 8.02M | 11.68M | -10.95M | 11.16M |